None listed
Conditions
Interventions
Intervention1: Nicotinamide Mononucleotide and Bioperine: Nicotinamide Mononucleotide (500 mg) and Bioperine (5 mg) capsule on Day-1 and Day-5 with 240ml of water.
Control Intervention1: Nicotinamide
Sponsors
Sami-Sabinsa Group Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male subjects and/or non-pregnant, non-lactating female subjects of childbearing potential and/or female subjects who have attained menopause. 2. Subject of age 18 to 45 years and above with BMI of 18.50 – 30.0 Kg/m2. 3. Subjects with normal vital parameters Blood Pressure (120/80 to 139/89 mmHg), pulse rate (70-100 beats/min) and temperature (97.00F-99.00F) and general clinical examination or those considered not clinically significant as decided by the investigator. 4. Subject who agree not consume coffee, tea, cola, chocolate or any other xanthine containing food or drinks within 3 days prior to start of the study and during the washout period. 5. Subject with no current or recent (within 2 weeks before randomization) treatment with any another investigational product. 6. Negative pregnancy test for females and does not plan to become pregnant during course of the study
Exclusion criteria
Exclusion criteria: 1. History of uncontrolled systemic diseases such as cardiac, gastrointestinal, respiratory, hepatic, renal, endocrine, neurological, metabolic, psychiatric and hematological disorders, based on clinical investigator’s judgment. 2. History of chronic alcoholism/ chronic smoking/ drug of abuse. 3. Subjects with hypersensitivity to NMN and BIOPERINE or any of the excipients. 4. Pregnant or lactating female subjects. 5. History of consumption of tobacco containing products within 48 hours prior to the proposed time of dosing. 6. Subjects who are positive for hepatitis B, anti-hepatitis C and Human Immunodeficiency Virus (HIV 1&2). 7. Present or past history of intake of vitamins & mineral supplements, herbal medicines or any prescription drugs other than the drugs already included in patient’s treatment regimen or over the counter (OTC) medicines within 14 days which can potentially alter/interfere / modify the PK parameters of NMN and BIOPERINE or any other medication judged to be clinically significant by the investigator. 8. Subjects who had donated blood/had any other blood loss over 01 unit of blood during the last 01 months before study initiation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the change in bioavailability between two different formulations - NMN Arm (A) vs NMN with Bioperine between Arm (B)Timepoint: Day-1 and Day-5 | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the efficacy, safety and tolerability of the above formulations in the study subjects by monitoring the incidence of any adverse events (AEs)Timepoint: Screening to Day-5 | — |
Countries
India
Contacts
Public ContactSatish G
Sami Sabinsa Group Limited
Outcome results
None listed